Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sera Prognostics Inc. is currently addressing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action involves 1 distinct examiner and is situated within 1 distinct art unit. Such a focused distribution indicates that the company's current prosecution efforts are not spread across multiple scientific disciplines or administrative divisions.
The busiest examiner identified in the data is BORGEEST, CHRISTINA M, who is handling 1 busiest examiner pending action. This 1 busiest examiner pending action constitutes the entirety of the company's 1 pending office action, making this examiner the sole arbiter of the portfolio's current progress. For practitioners, this means that the success of the portfolio's current phase relies entirely on the dialogue with BORGEEST, CHRISTINA M.
The alignment of 1 pending office action with 1 distinct art unit suggests a highly specific technical focus. Because there is only 1 distinct examiner involved, the company lacks the opportunity to compare prosecution speeds or allowance rates across different personnel. This concentration of 1 action under 1 examiner streamlines the communication process but centralizes the risk of the prosecution outcome.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORGEEST, CHRISTINA M | 1 | 55.7% | +21.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18592106 | BIOMARKER PAIRS FOR PREDICTING PRETERM BIRTH | BORGEEST, CHRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18592106 | BIOMARKER PAIRS FOR PREDICTING PRETERM BIRTH | BORGEEST, CHRISTINA M | 1675 | §112Other | Non-Final OA | — | Pending | Feb 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSera Prognostics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Christina M Borgeest has the most, with 1 of Sera Prognostics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
